Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model ...
Arabian Post on MSN
Immuno Cure deploys scientist team to manage research facility for therapeutic DNA vaccine for HIV at Center of International Innovation for Technology and Science
Another significant step towards the success of ICVAX®HONG KONG SAR – Media OutReach Newswire – 27 May 2026 – Immuno Cure Group (“Immuno Cure“), headquartered at Hong Kong Science Park, is pleased to ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant increase in stockholder equity and that the Company has entered into Amendment #2 to its existing ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules ...
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian CancerTopline results to be ...
There's mounting research to suggest that protecting people who are immuno-compromised from getting COVID is important not just for their sake – it could be critical in the effort to end the pandemic ...
Merck & Co.’s PD1 blocker pembrolizumab is a force to be reckoned with. Already a US$15 billion per year antibody, it is on track to becoming industry’s top-selling product by 2023. Approved for ...
Labroots is pleased to announce the 3rd annual event in the Immuno-Oncology Virtual Event Series taking place on April 30th, 2024. Immuno-Oncology is at the forefront of groundbreaking research in ...
This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American In 2017 the first immuno-oncology cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results